I have been in ALNY since the 30's, and i too wonder why it's still available. I like holding these plays for the really big hit, not a double, a 5 or 10 bagger. But a buyout short circuits that!
I also wonder why ISIS, and a few others haven't been bought.
The last big buyouts were last summer. I expect a few more in the next 2-3 months, but I hate it when one I own gets bought. Fast money, maybe what I would have gotten in 9 months, but them I need to find another that I have confidence in.
Will the buyouts be product companies (BMRN, QCOR), or pipeline companies like ISIS and ALNY? Time will tell.
silly reaction to earnings. they will have plenty of cash on hand at end of 2014 and their pipeline development is going well. this company is gonna be very big one day if it doesn't get bought out. A smart pharma would have already bought it when it was a billion and change....now look at the price tag...
I sold my wife and kids and bought more at $75 - what a gift
Are you cracked out ? This stock has just begun its move - it is headed 10 times higher from here. 3-5 years it will have a Market Cap of 40-50 Billion
This stock will crash along with many other over valued companies. Asian markets are down dramatically as I write this, 9:00 p.m. CST. Assets are going to move to safety, which means gold and silver in physical form. The COMEX may not be able to handle the huge increase in those demanding delivery. Some fools may go into bonds, but the counter party risk is way too great with all the debt the governments and individuals have taken on. Put on your hats people. We are going to live in some very interesting times.
icpt may seem expensive at 333 a share but its a little over 6 billion market cap not far from alny if alny was 333 the market cap will be around 18 billion
Thanks Asper.. It's been almost 6 months now since the ATTR in cardiac patients.. I can see the neuro Amyloid taking longer for clinical improvments to be available (although numbness, paresthesia, and pain could be measurable and reportable after weeks of therapy, I would imagine) . we have no word on these patients. They don't even mention what's happened to these patients. This bothers me. ALNY has a very good PR output... In gfact one of the more prolific frequent press releasers in the biotech industry especially when "good" things happen but become deatly silent on the stuff that doesn't work. What thappened to the RSV stuff?
I appreciate your response though.
There's an open label extension, after the phase II study, that includes clinical endpoints. And, there's a phase 3, double blind, placebo controlled study with clinical endpoints as well. You're right that so far, the studies have focused on effect of inhibiting the abnormal amyloid protein production and safety of the compound. The assumption is that such dramatic blocking of amyloid protein production would lead to clinical benefit, but of course these additional studies would help confirm or refute this. For chronic conditions such as neuropathy, you need a sufficiently long enough study to prove whether your compound works over placebo. Hence, the phase 3 study looks at clinical endpoints after 18 months.
There's certainly a possibility that even with robust knockdown effect, we don't see dramatic or demonstrable clinical efficacy. You're certainly free to trade accordingly if you think despite all the data so far, that clinical endpoints won't be reached with current studies.
ALNY must see something there that Merck couldn't - the huge discount for SIRNA contributes substantially to the price bump and justifies the lofty price...just hang on and be patient...more good things to come....